Sarepta Therapeutics - SRPT Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SRPT shares.
View SRPT analyst ratings or view top-rated stocks.

9 Wall Street analysts have issued 12 month price targets for Sarepta Therapeutics' shares. Their SRPT share price forecasts range from $114.00 to $190.00. On average, they predict the company's stock price to reach $150.14 in the next twelve months. This suggests a possible upside of 27.2% from the stock's current price.
View analysts price targets for SRPT or view top-rated stocks among Wall Street analysts.

Sarepta Therapeutics' stock was trading at $129.58 at the beginning of 2023. Since then, SRPT shares have decreased by 8.9% and is now trading at $118.04.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our SRPT earnings forecast.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) issued its quarterly earnings data on Wednesday, November, 3rd. The biotechnology company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($1.86) by $1.26. The biotechnology company had revenue of $189.41 million for the quarter, compared to analysts' expectations of $170.13 million. Sarepta Therapeutics had a negative net margin of 81.76% and a negative trailing twelve-month return on equity of 97.37%. During the same period last year, the company posted ($2.50) EPS.

15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS).

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

Sarepta Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.83%), Allspring Global Investments Holdings LLC (0.43%), National Bank of Canada FI (0.34%), Mizuho Markets Americas LLC (0.22%), Wolverine Asset Management LLC (0.00%) and Pinnacle Associates Ltd. (0.11%). Insiders that own company stock include David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Michael Andrew Chambers, Richard Barry and Stephen Mayo.
View institutional ownership trends.

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SRPT stock can currently be purchased for approximately $118.04.

Sarepta Therapeutics (NASDAQ:SRPT) has a market capitalization of $10.36 billion and generates $701.89 million in revenue each year. The biotechnology company earns $-418,780,000.00 in net income (profit) each year or ($8.21) on an earnings per share basis.

The company employs 840 workers across the globe.

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The official website for the company is www.sareptatherapeutics.com. The biotechnology company can be reached via phone at (617) 274-4000, via email at investors@sarepta.com, or via fax at 425-354-5038.